The World Health Organization (WHO) is updating its Abortion Care Guideline by transitioning it to a living guideline format — one that allows for targeted, evidence-based revisions as new research or implementation challenges emerge. The first update on the agenda is Recommendation 27b, which covers repeat dosing of the misoprostol-alone regimen for medical abortion at less than 12 weeks of gestation.

To support this process, a subset of the original Guideline Development Group (GDG) — comprising experts who contributed to the original guideline — has been reconvened. Their role is to review the latest synthesized evidence and formulate updated recommendations in line with WHO's handbook for guideline development.

Key Takeaways:

• The WHO's shift to a living guideline model enables faster, more responsive updates to abortion care standards
• The GDG will specifically re-examine evidence on repeat misoprostol dosing for abortions under 12 weeks
• Expert biographies are publicly posted for 14 days, with a comment and conflict-of-interest window open until October 29, 2026

Why it matters: Misoprostol-alone regimens are widely used in low-resource settings where mifepristone may not be available. Updating dosing guidance could directly improve safety and efficacy for people seeking early medical abortion globally.